Q-omics provides the consensus-scored MIR4520-1 profile across patient tissues and cancer cell-line models. MIR4520-1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MIR4520-1 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, MIR4520-1 RNA expression shows 13,482 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight COAD, KICH, and DLBC as cancer lineages where MIR4520-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4520-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4520-1 survival associations across molecular data types. MIR4520-1 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4520-1 RNA expression–survival associations across cancer types. High MIR4520-1 expression shows unfavorable associations in COAD, KICH and TGCT, but favorable associations in HNSC, UCS and LUAD. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for MIR4520-1 RNA expression.
This table summarizes MIR4520-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4520-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4520-1 shows lower tumor expression in KICH, COAD and THCA and higher tumor expression in HNSC, KIRP and LUSC. The KICH box plot shows higher MIR4520-1 RNA expression in normal versus tumor tissue (log2 FC = −0.968, t-test p < 0.001).
This table shows molecular features associated with MIR4520-1 in patient tissues and cancer cell lines. In patient samples, MIR4520-1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
